Form 4: STOK GC Sells 13,712 Shares via 10b5-1 Plan

Stoke Therapeutics General Counsel Jonathan Allan sold 13,712 shares of common stock at $15 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported a sale of common stock.
• On August 13, 2025, Allan disposed of 13,712 shares of STOK common stock.
• The shares were sold at a price of $15 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
• Following this transaction, Allan beneficially owns 19,631 shares of common stock.
• The reported total includes 1,778 shares acquired through the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: Neutral. While an insider sale can be seen negatively, the execution under a Rule 10b5-1 plan suggests a pre-planned liquidity event rather than a reaction to new negative information. The insider also retains a significant holding and participates in ESPP.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled sale rather than a reaction to immediate negative news.
• The reporting person still retains a significant holding of 19,631 shares after the sale.
• The reporting person acquired 1,778 shares through the Employee Stock Purchase Plan, demonstrating continued participation in company equity programs.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity exposure.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This filing is a routine insider transaction report and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: May interpret the insider sale differently; some may see it as a routine liquidity event, while others might view it as a reduction in insider confidence.

Key Dates

Recommendation

The filing details a pre-scheduled insider stock sale by the General Counsel under a Rule 10b5-1 plan. Such sales are typically for personal financial planning and do not necessarily reflect a change in the company's fundamental outlook. The insider retains a substantial holding, and the transaction itself does not provide new information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as this is a routine disclosure.

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Jonathan Allan, Stock Sale, Rule 10b5-1, General Counsel, Equity Transaction, Biotechnology